Last reviewed · How we verify
ABvac40
At a glance
| Generic name | ABvac40 |
|---|---|
| Sponsor | Araclon Biotech S.L. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD (PHASE2)
- Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |